Amarin Corporation plc - ADR logo

Amarin Corporation plc - ADR (EH3A)

Market Closed
5 Jun, 20:00
8. 16
0
0%
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
- Eps
8.16
Previous Close
Day Range
8.16 8.16
Year Range
6.96 15.3

Summary

EH3A closed Thursday higher at €8.16, an increase of 0% from Wednesday's close, completing a monthly increase of 0% or €0. Over the past 12 months, EH3A stock lost -10.92%.
EH3A is not paying dividends to its shareholders.
The last earnings report, released on Apr 18, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Amarin Corporation plc - ADR has completed 1 stock splits, with the recent split occurring on Apr 11, 2025.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
Want to track EH3A and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

EH3A Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y

Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y

AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.

Zacks | 1 month ago
Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

Amarin Corporation plc (NASDAQ:AMRN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Mark Marmur - Vice President of Corporate Communications and Investor Relations Aaron Berg - President and Chief Executive Officer Peter Fishman - Vice President and Global Controller Steven Ketchum - Executive Vice President, President of R&D and Chief Scientific Officer Conference Call Participants Operator Welcome to Amarin Corporation's Conference Call to discuss its First Quarter 2025 Business Update and Financial Results. I would like to turn the conference call over to Mark Marmur, Vice President, Corporate Communications and Investor Relations at Amarin.

Seekingalpha | 1 month ago
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

-- Nasdaq Compliance Follows ADS Ratio Change to Secure Company's Public Listing -- -- Amarin Remains Focused on Maximizing the Global Value of VASCEPA/VAZKEPA –

Globenewswire | 1 month ago

Amarin Corporation plc - ADR Dividends

EH3A is not paying dividends to its shareholders.

Amarin Corporation plc - ADR Earnings

18 Apr 2025 Date
-
Cons. EPS
-
EPS
12 Mar 2025 Date
-
Cons. EPS
-
EPS
31 Jul 2024 Date
-
Cons. EPS
-
EPS
1 May 2024 Date
-
Cons. EPS
-
EPS
29 Feb 2024 Date
-
Cons. EPS
-
EPS
EH3A is not paying dividends to its shareholders.
18 Apr 2025 Date
-
Cons. EPS
-
EPS
12 Mar 2025 Date
-
Cons. EPS
-
EPS
31 Jul 2024 Date
-
Cons. EPS
-
EPS
1 May 2024 Date
-
Cons. EPS
-
EPS
29 Feb 2024 Date
-
Cons. EPS
-
EPS

Amarin Corporation plc - ADR (EH3A) FAQ

What is the stock price today?

The current price is €8.16.

On which exchange is it traded?

Amarin Corporation plc - ADR is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is EH3A.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Amarin Corporation plc - ADR ever had a stock split?

Amarin Corporation plc - ADR had 1 splits and the recent split was on Apr 11, 2025.

Amarin Corporation plc - ADR Profile

Biotechnology Industry
Healthcare Sector
Mr. Aaron D. Berg CEO
XSTU Exchange
US0231112063 ISIN
IE Country
275 Employees
- Last Dividend
11 Apr 2025 Last Split
- IPO Date

Overview

Amarin Corporation plc stands as a noteworthy entity within the pharmaceutical landscape, dedicating its efforts to developing and commercializing therapeutic treatments aimed at combating cardiovascular diseases. With a geographical footprint spanning the United States, various European countries, Canada, Lebanon, and the United Arab Emirates, Amarin has established a significant presence in the global healthcare sector. The company's journey began under the name Ethical Holdings plc but underwent a rebranding to Amarin Corporation plc in 1999, marking a new chapter in its history. Since its inception in 1989, Amarin has been headquartered in Dublin, Ireland, serving as a testament to its enduring commitment to advancing cardiovascular health through innovative pharmaceutical solutions. At the heart of its collaborative endeavors is a strategic partnership with Mochida Pharmaceutical Co., Ltd., focusing on the development and commercialization of drug products and new therapeutic indications derived from the active pharmaceutical ingredient in its flagship product, Vascepa.

Products and Services

  • VASCEPA

VASCEPA stands out as Amarin Corporation plc's premier product offering, distinguished by its formulation as a prescription-only omega-3 fatty acid. This distinctive pharmacological product is specifically designed as an adjunct to diet for the purpose of reducing triglyceride levels in adult patients diagnosed with severe hypertriglyceridemia. The commercialization of VASCEPA primarily targets wholesalers and specialty pharmacy providers, thereby ensuring its accessibility to the patient population in need of this critical intervention for managing cardiovascular health. Through this endeavor, Amarin accentuates its commitment to addressing the intricate challenges associated with cardiovascular diseases, leveraging the therapeutic potential of omega-3 fatty acids to enhance patient outcomes.

Contact Information

Address: Grand Canal Docklands
Phone: 353 1 669 9020